Association of pentraxin-3 with the severity of rheumatic mitral valve stenosis

Basit Öğe Kaydı
dc.contributor.authorPolat, Nihat
dc.contributor.authorYildiz, Abdulkadir
dc.contributor.authorAlan, Sait
dc.contributor.authorToprak, Nizamettin
dc.date.accessioned2024-04-24T17:07:54Z
dc.date.available2024-04-24T17:07:54Z
dc.date.issued2015
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjectives Inflammation is involved in the pathogenesis of rheumatic mitral valve stenosis (RMVS). Pentraxin-3 (PTX3) indicates the inflammatory state of humans. However, circulating PTX3 levels in patients with RMVS, remain largely unknown. In this study, we investigated whether there is an association between the severity of RMVS and PTX3. Methods All patients diagnosed as rheumatic mitral valvular stenosis between December 2013 and April 2014 were included in the study. We investigated circulating PTX3 and high-sensitivity C-reactive protein (hsCRP) levels in patients with RMVS and healthy controls. Results The study population included 72 subjects (41 patients with RMVS and 31 healthy subjects, 56 female) with a mean age of 40 +/- 13 years. Patients with RMVS had higher left atrial diameters than healthy subjects. PTX3 and hsCRP were significantly higher in patients with RMVS when compared to control subjects and this difference was more significant in PTX3 compared to hsCRP (3.37 +/- 1.11 vs 2.86 +/- 0.59, P = 0.014 and 2.36 +/- 1.48 vs 1.72 +/- 0.73, P = 0.019, respectively). PTX3 was positively correlated with Wilkins score, mitral valvular area, mitral pressure gradient and left atrium diameter. Conclusions We demonstrated that plasma PTX3 and hsCRP levels were increased in patients with RMVS. Compared to hsCRP, PTX3 was more closely related with the severity of mitral valve stenosis. These findings suggest that PTX3 may participate in the pathophysiology of RMVS.en_US
dc.identifier.doi10.1080/AC.70.4.3094649
dc.identifier.endpage413en_US
dc.identifier.issn0001-5385
dc.identifier.issn1784-973X
dc.identifier.issue4en_US
dc.identifier.pmid26455242
dc.identifier.scopus2-s2.0-84939815678
dc.identifier.scopusqualityQ3
dc.identifier.startpage409en_US
dc.identifier.urihttps://doi.org/10.1080/AC.70.4.3094649
dc.identifier.urihttps://hdl.handle.net/11468/17087
dc.identifier.volume70en_US
dc.identifier.wosWOS:000360326200005
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofActa Cardiologica
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRheumatic Valve Diseaseen_US
dc.subjectMitral Stenosisen_US
dc.subjectInflammationen_US
dc.subjectPentraxinen_US
dc.subjectC-Reactive Proteinen_US
dc.titleAssociation of pentraxin-3 with the severity of rheumatic mitral valve stenosisen_US
dc.titleAssociation of pentraxin-3 with the severity of rheumatic mitral valve stenosis
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu